19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.

Janssen Research and Development
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.

Merck Research Laboratories
Lysine demethylases inhibitors.

Kyoto Prefectural University of Medicine
Structural basis for binding of cyclic 2-oxoglutarate analogues to factor-inhibiting hypoxia-inducible factor.

University of Oxford
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.

Nagoya City University
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.

University College London
Novel Compounds as PHD Inhibitors for Treating Heart, Lung, Liver, and Kidney Diseases.

Smith, Gambrell & Russell
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.

Merck Research Laboratories
Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.

Oxford University
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.

Merck
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.

Cadila Healthcare
1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.

Takeda California
Methods of inhibiting formation of alpha synuclein aggregates

University of California
Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer

Korea Research Institute of Chemical Technology
ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF

Bolt Biotherapeutics
Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof

Debiopharm International
Fused cyclopentyl antagonists of CCR2

Janssen Pharmaceutica